文章：

在多发性骨髓瘤中具有单药活性的新研究药物

New investigational drugs with single-agent activity in multiple myeloma

原文发布日期：2016-07-29

DOI: 10.1038/bcj.2016.53

类型: Review

开放获取: 是

英文摘要：

The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been a dramatic improvement in the outcome of MM in the last decade, probably more than any other malignancy. Numerous agents continue to be studied in preclinical models and in clinical trials, with many demonstrating clinical efficacy that appears promising enough to have a trajectory for regulatory approval. The purpose of this article is to summarize the current data and provide perspective on new investigational agents with promising single-agent activity in MM. The agents reviewed include Isatuximab, an anti-CD38 monoclonal antibody; marizomib, a new proteasome inhibitor; oprozomib, an oral proteasome inhibitor; filanesib (ARRY-520), a kinesin spindle protein inhibitor; dinaciclib, a cyclin-dependent kinase inhibitor; venetoclax (ABT-199), a selective BCL-2 inhibitor; and LGH-447, pan PIM kinase inhibitor.

摘要翻译： 

多发性骨髓瘤（MM）的治疗正在迅速发展。2015年，美国批准了四种药物（帕比司他、伊沙佐米、达雷妥尤单抗和埃罗妥珠单抗）用于治疗多发性骨髓瘤。得益于诊断和治疗的改进，过去十年中多发性骨髓瘤的治疗结局显著改善，其进展可能超过任何其他恶性肿瘤。许多药物仍在临床前模型和临床试验中持续研究，其中许多显示出临床疗效，前景广阔，有望获得监管批准。本文旨在总结现有数据，并对具有良好单药活性的新研究性药物提供展望。 reviewed的药物包括抗CD38单克隆抗体伊沙妥昔单抗；新型蛋白酶体抑制剂马立佐米；口服蛋白酶体抑制剂奥普佐米；驱动蛋白纺锤体抑制剂菲拉奈塞（ARRY-520）；细胞周期蛋白依赖性激酶抑制剂地那西塞；选择性BCL-2抑制剂维奈托克（ABT-199）；以及泛PIM激酶抑制剂LGH-447。

原文链接：

New investigational drugs with single-agent activity in multiple myeloma